trending Market Intelligence /marketintelligence/en/news-insights/trending/8daw78zwi8yb6tkbrnfrqq2 content esgSubNav
In This List

Kuros Biosciences nominates CEO, directors

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Kuros Biosciences nominates CEO, directors

Kuros Biosciences AG will propose the appointment of Joost de Bruijn as CEO, along with three independent nonexecutive directors, at its annual general meeting June 14.

De Bruijn was the founder and CEO of Progentix Orthobiology BV and Xpand biotechnology BV. He has more than 28 years of experience in academia and the life science industry.

Meanwhile, the Swiss biotech is proposing Jason Hannon, Scott Bruder and Oliver Walker to serve on its board as independent nonexecutive directors.

Hannon would replace Didier Cowling, who will not stand for re-election. Hannon is CEO and a member of the board of Mainstay Medical International PLC.

Bruder would replace Frank-Jan van der Velden, who will not stand for re-election. Bruder has worked previously at DePuy Biologics, now known as Depuy Synthes; Johnson & Johnson Regenerative Therapeutics LLC; Becton Dickinson and Co.; and Stryker Corp.

Walker would replace Harry Welten, who will also not stand for re-election. Walker was previously CFO at Nobel Biocare, Sonova and Stratec.